RhumbLine Advisers’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

RhumbLine Advisers’s Portfolio PAND Stock Details PAND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,368	Closed	-$743K	–	3212
2021 Q1	$743K	Buy	+12,368	New	+$448K	﹤0.01%	2316

RhumbLine Advisers's PAND Position: Q2 2021 in Review

RhumbLine Advisers sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 12,368 shares — an estimated $743K sold.

RhumbLine Advisers first reported a position in PAND in Q1 2021 and held it in 1 quarter. The position peaked at $743K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

RhumbLine Advisers reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
RhumbLine Advisers sold 12,368 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $743K.
RhumbLine Advisers first reported a position in Pandion Therapeutics Inc. Common Stock in Q1 2021 and held it in 1 quarter.
RhumbLine Advisers's Pandion Therapeutics Inc. Common Stock position peaked at $743K in Q1 2021.
0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.